secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2023-09-05T23:59:59+00:00
Accession:  0001193125-23-228076
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea appoints Scott Burrows as CFO, Heidy Abreu King-Jones as CLO; prior CFO transitions to advisory role
--------------------------------------------------------------------------------

- Scott Burrows appointed CFO effective Sept 1, 2023, succeeding Jonathan Alspaugh; base salary $455K, target bonus 40%, sign-on $115K.
- Heidy Abreu King-Jones appointed Chief Legal Officer & Corporate Secretary; both report to COO Cameron Turtle.
- Jonathan Alspaugh transitions to strategic advisory role through Dec 31, 2023; he was President and CFO.
- Burrows received inducement options for 10,121,441 shares and 3,373,814 RSUs; King-Jones options for 13,495,255 shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523228076/0001193125-23-228076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312523228076/d437285d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-228076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer